352 Federal Register / Vol. 61, No. 3 / Thursday, January 4, 1996 / Notices

South LaSalle Street, Chicago, Illinois

60690:

1. Firstbank of Illinois Co.,

Springfield, Illinois; to engage de novo

through its subsidiary, MidCountry

Financial, Inc., Highland, Illinois, in

consumer finance business, pursuant to

§ 225.25(b)(1)(i) of the Board’s

Regulation Y.

Board of Governors of the Federal Reserve

System, December 28, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 96–96 Filed 1–3–96; 8:45 am]

BILLING CODE 6210–01–F

National Bank of Greece, et al.;

Acquisitions of Companies Engaged in

Permissible Nonbanking Activities

The organizations listed in this notice

have applied under § 225.23(a)(2) or (f)

of the Board’s Regulation Y (12 CFR

225.23(a)(2) or (f)) for the Board’s

approval under section 4(c)(8) of the

Bank Holding Company Act (12 U.S.C.

1843(c)(8)) and § 225.21(a) of Regulation

Y (12 CFR 225.21(a)) to acquire or

control voting securities or assets of a

company engaged in a nonbanking

activity that is listed in § 225.25 of

Regulation Y as closely related to

banking and permissible for bank

holding companies. Unless otherwise

noted, such activities will be conducted

throughout the United States.

Each application is available for

immediate inspection at the Federal

Reserve Bank indicated. Once the

application has been accepted for

processing, it will also be available for

inspection at the offices of the Board of

Governors. Interested persons may

express their views in writing on the

question whether consummation of the

proposal can ‘‘reasonably be expected to

produce benefits to the public, such as

greater convenience, increased

competition, or gains in efficiency, that

outweigh possible adverse effects, such

as undue concentration of resources,

decreased or unfair competition,

conflicts of interests, or unsound

banking practices.’’ Any request for a

hearing on this question must be

accompanied by a statement of the

reasons a written presentation would

not suffice in lieu of a hearing,

identifying specifically any questions of

fact that are in dispute, summarizing the

evidence that would be presented at a

hearing, and indicating how the party

commenting would be aggrieved by

approval of the proposal.

Unless otherwise noted, comments

regarding each of these applications

must be received at the Reserve Bank

indicated for the application or the

offices of the Board of Governors not

later than January 22, 1996.

A. Federal Reserve Bank of New

York (William L. Rutledge, Senior Vice

President) 33 Liberty Street, New York,

New York 10045:

1. National Bank of Greece, Athens,

Greece; to retain shares of Worthington

Limited Partnership, New York, New

York, and thereby indirectly engage in

acquiring and servicing loans and leases

pursuant to §§ 225.25(b)(1) and (b)(5) of

the Board’s Regulation Y.

B. Federal Reserve Bank of San

Francisco (Kenneth R. Binning,

Director, Bank Holding Company) 101

Market Street, San Francisco, California

94105:

1. The Sumitomo Bank, Limited,

Osaka, Japan; to acquire through The

Sumitomo Bank New York Trust

Company, New York, New York, the

trust business of Daiwa Bank Trust

Company, New York, New York, and

the custody business of the New York

branch of The Daiwa Bank, Limited,

Osaka, Japan, and thereby engage in

trust company functions, pusuant to §

225.25(b)(3) of the Board’s Regulation Y.

Board of Governors of the Federal Reserve

System, December 28, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 96–97 Filed 1–3–96; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 93P–0310]

White Chocolate Deviating From

Identity Standard; Amendment of

Temporary Permit for Market Testing

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing

that it is amending an extended

temporary permit issued to Hershey

Foods Corp. (Hershey) to market test

products identified, in part, as ‘‘white

chocolate’’ that deviate from the U.S.

standards of identity for chocolate

products, e.g., chocolate liquor, sweet

chocolate, milk chocolate, buttermilk

chocolate, skim milk chocolate, or

mixed dairy product chocolates. The

purpose of the amendment to the

extended temporary permit is to allow

Hershey to collect data on consumer

acceptance of a different product,

containing white chocolate, that also

contains chocolate cookies, and to

identify mass production problems.

FOR FURTHER INFORMATION CONTACT:

Nannie H. Rainey, Center for Food

Safety and Applied Nutrition (HFS–

158), Food and Drug Administration,

200 C St. SW., Washington, DC 20204,

202–205–5099.

SUPPLEMENTARY INFORMATION: In

accordance with § 130.17 (21 CFR

130.17) concerning temporary permits,

FDA gave notice in the Federal Register

of November 5, 1993 (58 FR 59050), that

a temporary permit had been issued to

Hershey Foods Corp., P.O. Box 810,

Hershey, PA 17033. The temporary

permit was issued to market test

products containing a component

designated as ‘‘white chocolate’’ and to

facilitate market testing of foods

deviating from the requirements of the

standards of identity promulgated under

section 401 of the Federal Food, Drug,

and Cosmetic Act (21 U.S.C. 341). The

white chocolate component of these

products deviates from the standards of

identity for certain chocolate products,

e.g., chocolate liquor (21 CFR 163.111),

sweet chocolate (21 CFR 163.123), milk

chocolate (21 CFR 163.130), buttermilk

chocolate (21 CFR 163.135), skim milk

chocolate (21 CFR 163.140), or mixed

dairy product chocolates (21 CFR

163.145) in that: (1) It is prepared

without the nonfat components of the

ground cacao nibs, but contains the fat

(cocoa butter) expressed from the

ground cacao nibs; and (2) safe and

suitable antioxidants are added. The test

component meets all the other

requirements of the standards for

chocolate products in 21 CFR part 163.

Subsequently, Hershey requested that

their temporary permit (Docket No.

93P–0310) be extended to allow for

additional time for the firm to continue

to collect data on consumer acceptance

of the products while the agency takes

action on two petitions (Docket Nos.

86P–0297/CP 2 and 86P–0297/CP 3 (see

59 FR 67302, December 29, 1994, for

discussion)) to establish a standard of

identity for white chocolate that were

submitted by Hershey and by the

Chocolate Manufacturers Association.

FDA granted the request for the

extension and provided for continued

testing on an annual basis of up to

21,800,000 kilograms (kg) (48,000,000

pounds (lb)) of the test product. The test

products bear the fanciful names

‘‘Hershey’s Hugs, Mini Hershey’s Kisses

Hugged by White Chocolate’’ and

‘‘Hershey’s Hugs, Mini Hershey’s Kisses

Hugged by White Chocolate, with

Almonds.’’ In the Federal Register of

December 29, 1994 (59 FR 67302), FDA

extended the expiration date of the
Federal Register / Vol. 61, No. 3 / Thursday, January 4, 1996 / Notices 353

permit so that the permit expires either

on the effective date of a final rule to

establish a standard of identity for white

chocolate, which may result from the

petitions, or 30 days after termination of

such rulemaking.

Hershey is now requesting that the

extended temporary permit be amended

to provide for up to 13,600,000 kg

(30,000,000 lb) of a different product,

containing white chocolate, that also

contains chocolate cookies. Hershey is

also requesting that the permit be

amended to allow an additional plant

where this product can be

manufactured.

The agency finds that it is in the

interest of the consumer to amend the

extended temporary permit to allow for

market testing of another product

containing white chocolate. Therefore,

under the provisions of § 130.17(f), FDA

is modifying the extended temporary

permit granted to Hershey to provide for

the market testing of up to 13,600,000 kg

(30,000,000 lb) of the new test product

on an annual basis in addition to the

21,800,000 kg (48,000,000 lb) of test

product authorized in the original

permit. The new test product, in bar and

bite size forms, will bear the fanciful

name ‘‘Hershey’s Cookies ’n’ Creme

Chocolate Cookie Bits in White

Chocolate.’’ The white chocolate meets

the compositional requirements of the

current temporary permit. FDA is also

modifying the extended temporary

permit to provide for an additional plant

at Hershey Chocolate, U.S.A., 19 East

Chocolate Ave., Hershey, PA 17033,

where the product may be

manufactured. The product will be

distributed nationwide.

Each of the ingredients used in the

food must be declared on the label as

required by the applicable sections of 21

CFR part 101. This amended extended

permit expires either on the effective

date of a final rule to establish a

standard of identity for white chocolate,

which may result from the petitions, or

30 days after termination of such

rulemaking. All other conditions and

terms of the extended permit remain the

same.

Dated: December 15, 1995.

F. Edward Scarbrough,

Director, Office of Food Labeling, Center for

Food Safety and Applied Nutrition.

[FR Doc. 96–124 Filed 1–3–96; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 95S–0199]

Report of the Fluoroquinolone Working

Group; Availability

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing the

availability of the report of the Center

for Veterinary Medicine’s (CVM’s)

Fluoroquinolone Working Group

(FQWG). The report addresses issues

and contains recommendations

regarding policies and procedures

related to approval of fluoroquinolone

(FQ) antimicrobial drugs in food

animals. The report of the FQWG is in

response to concerns that approval of

FQ drugs for use in food animals may

result in increased development of FQ

resistance in zoonotic organisms

harbored by food animals that are

transmitted to humans and cause

disease.

DATES: Written comments on the report

may be submitted at any time.

ADDRESSES: Submit written requests for

single copies of the report to the

Communication and Education Branch

(HFV–12), Center for Veterinary

Medicine, Food and Drug

Administration, 7500 Standish Pl.,

Rockville, MD 20855. Send two selfaddressed adhesive labels to assist that

office in processing your requests.

Submit written comments on the report

to the Dockets Management Branch

(HFA–305), Food and Drug

Administration, rm. 1–23, 12420

Parklawn Dr., Rockville MD, 20857.

Requests and comments should be

identified with the docket number

found in brackets in the heading of this

document. A copy of the report and

received comments are available for

public examination in the Dockets

Management Branch between 9 a.m. and

4 p.m., Monday through Friday.

FOR FURTHER INFORMATION CONTACT:

Linda A. Grassie, Center for Veterinary

Medicine (HFV–12), Food and Drug

Administration, 7500 Standish Pl.,

Rockville, MD 20855, 301–594–1755.

SUPPLEMENTARY INFORMATION: FDA is

announcing the availability of the report

of CVM’s FQWG. The report addresses

issues and recommendations concerning

approval of FQ drugs for use in food

animals. In response to concerns that

approval of FQ drugs for use in food

animals may result in increased

development of FQ resistance in

zoonotic organisms harbored by food

animals that are transmitted to humans

and cause disease. FDA convened a

joint meeting of the CVM and Center for

Drug Evaluation and Research advisory

committees on May 11 and 12, 1994.

Members of the joint advisory

committee stated that FQ drugs could be

approved for use in food animals, if

CVM restricts their use so that FQ’s are

safe and effective under approved

conditions of use and recommended

that CVM monitor the emergence of FQ

resistance. In response to the public

health concerns that were raised, CVM

formed the FQWG to provide

recommendations of policies and

procedures relevant to the approval of

FQ drugs in food animals. FDA is

announcing that the report of the FQWG

has been accepted by the Director, CVM,

and is available for public inspection

and comment.

Interested persons may, at any time,

submit to the Dockets Management

Branch (address above) written

comments on the report of CVM’s

FQWG. Two copies of any comments

are to be submitted, except that

individuals may submit one copy.

Comments are to be identified with the

docket number found in the heading of

this document. The report, appendices,

and comments may be seen at the

Dockets Management Branch (address

above), between 9 a.m. and 4 p.m.,

Monday through Friday.

The report and recommendations

represent the agency’s current position

on the issues discussed therein,

however, they do not create or confer

any rights, privileges, or benefits for or

on any person, nor do they operate to

bind FDA in any way. CVM will

consider any comments received in

determining the continued

appropriateness of the

recommendations in the report

regarding the approval of FQ’s for

animal use.

Dated: December 27, 1995.

William K. Hubbard,

Associate Commissioner for Policy

Coordination.

[FR Doc. 96–125 Filed 1–3–96; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HOUSING AND

URBAN DEVELOPMENT

Office of the Secretary

[Docket No. FR–4007–D–01]

Delegation of Concurrent Authority to

the Deputy Secretary

AGENCY: Office of The Secretary, HUD.

ACTION: Notice of delegation of

concurrent authority.